In a decisive move to address emerging public safety concerns, the U.S. Drug Enforcement Administration (DEA) has officially moved to exert tighter control over a new class of synthetic substances associated with Mitragyna speciosa, commonly known as kratom. On August 25, 2026, the agency issued a temporary scheduling order that places three high-potency synthetic alkaloids—mitragynine pseudoindoxyl, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act (CSA).
This regulatory action marks a significant pivot in the federal government’s approach to the kratom market. While traditional, plant-based kratom leaf products remain outside this specific scheduling order, the DEA is aggressively targeting the “proliferation” of semi-synthetic and synthetic derivatives that the agency claims are being marketed with deceptive health claims and possess dangerous, opioid-like potency.
Chronology of Regulatory Action
The path to the current scheduling order began earlier this summer, following a growing body of evidence regarding the rapid evolution of products derived from or related to kratom’s primary psychoactive alkaloids.
- July 1, 2026: The DEA published two critical Federal Register notices signaling its intent to exercise emergency scheduling authority. One notice specifically addressed the synthetic trio of mitragynine pseudoindoxyl, MGM-15, and MGM-16. A secondary notice proposed establishing strict threshold levels for 7-hydroxymitragynine (7-OH), a naturally occurring but highly potent alkaloid found in the plant.
- July 6, 2026: The notices were officially entered into the Federal Register, initiating a mandatory 30-day public comment period. During this window, the Office of the Assistant Secretary for Health (OASH) collected data and feedback from stakeholders to advise the Attorney General on the necessity of the scheduling.
- August 25, 2026: Having reviewed the submitted comments and data, the DEA formalized its order. The substances were classified as Schedule I, effective immediately.
- September 10, 2026: This date serves as the current deadline for the extended public comment period specifically regarding the proposed thresholds for 7-OH, as the government continues to refine its approach to regulating products containing high concentrations of this substance.
The Science of Risk: Why These Substances Were Targeted
The DEA’s justification for this emergency scheduling hinges on the pharmacological profile of these synthetic compounds. Unlike traditional botanical kratom, which contains a complex profile of alkaloids, the targeted substances are refined, concentrated, or synthesized to act as potent mu-opioid receptor (MOR) agonists.
Pharmacological Potency
According to the DEA’s findings, the risk profile of these substances mirrors that of traditional opioids like morphine and fentanyl. The data is particularly concerning regarding potency:
- Mitragynine pseudoindoxyl: Preclinical data suggests this compound is approximately 100 times more potent than mitragynine, the primary alkaloid in the kratom leaf.
- MGM-15 and MGM-16: These synthetic derivatives exhibit a potency estimated to be 50 to 240 times that of morphine.
Animal models have consistently shown that these substances induce signs of physical dependence and respiratory depression—the hallmark life-threatening risks associated with classic opioid abuse.
Deceptive Marketing and Public Health
The DEA has expressed alarm over the “low barrier to entry” for these products. They are often marketed in colorful, consumer-friendly formats—such as chews or flavored extracts—that mask their intense pharmacological effects. Manufacturers have frequently utilized misleading advertising, suggesting that these synthetic products provide the same benefits as natural kratom, such as stress relief or mental clarity, while failing to disclose the severe risks of addiction and potential toxicity.
By 2022, the prevalence of use for these substances had reached an estimated 2 million individuals, highlighting the urgency with which the DEA felt it necessary to intervene to prevent a broader public health crisis.
Official Responses and Administrative Procedures
The federal government’s stance is supported by the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA). Both agencies have confirmed that these synthetic substances possess no recognized medical use in the United States and present a high potential for abuse.
A critical component of this legal process involves the delegation of authority. Under the CSA, the Attorney General possesses the power to schedule substances, a task delegated to the DEA Administrator. Before the August 25 order, the Assistant Secretary for Health confirmed that there were no active Investigational New Drug (IND) or New Drug Application (NDA) filings for these three substances, further reinforcing their status as non-medical, illicit-risk compounds.
The DEA maintains that this temporary scheduling—which lasts for two years with a potential one-year extension—does not require the traditional notice-and-comment procedure usually associated with permanent rule-making, as it is being enacted to avoid an "imminent hazard to public safety."
The Legal and Regulatory Implications
The transition of these substances to Schedule I status has immediate and far-reaching consequences for manufacturers, retailers, and the scientific research community.
Impact on Retailers and Manufacturers
Effective August 25, 2026, the retail sale of any product containing mitragynine pseudoindoxyl, MGM-15, or MGM-16 is strictly prohibited. Retailers are required to cease the sale of these products immediately. Possession of these substances without a valid, specialized Schedule I registration from the DEA is a violation of federal law, subject to civil and criminal sanctions. Businesses currently holding these substances are mandated to either surrender them or comply with rigorous, and often cost-prohibitive, regulatory storage and security requirements.
Impact on the Research Community
For scientists and academic institutions, the ruling does not ban research, but it drastically changes the legal landscape. Researchers who wish to study these substances must now obtain a specific Schedule I license. This involves a high level of administrative scrutiny, enhanced physical security for lab facilities, and detailed record-keeping that satisfies DEA mandates.
The 7-OH Threshold Ambiguity
While the three aforementioned substances are now fully scheduled, the status of 7-hydroxymitragynine (7-OH) remains subject to a complex threshold debate. The DEA has proposed that any botanical material of Mitragyna speciosa containing more than 0.050% of 7-OH on a dry weight basis may be subject to regulation.
Legal experts, such as Brian Malkin, have pointed to a significant ambiguity in the DEA’s language. The agency uses the term "article" when referring to products that might fall under this threshold, a term that is not clearly defined within the CSA. In the context of the Federal Food, Drug and Cosmetic Act (FD&C Act), "article" has historically been debated in courts as referring to either the "finished product" or the "individual dosage unit." This lack of clarity leaves a gray area for manufacturers of standard kratom products who must ensure their botanical materials do not inadvertently cross into regulated territory due to natural variations in alkaloid content.
Moving Forward: A Shifting Landscape
The DEA’s recent actions serve as a stern warning to the supplement and alternative health industry. While the agency has not banned botanical kratom leaf itself, the shift toward regulating "semi-synthetic" derivatives suggests that the era of unregulated, high-potency kratom extracts is coming to an end.
For the industry, the primary takeaway is the necessity for transparency and compliance. Manufacturers who have pivoted toward "enhanced" or synthetic formulations are now in the crosshairs of federal law enforcement. Businesses operating in this space are strongly advised to:
- Audit Product Inventories: Ensure that no products contain the newly scheduled synthetic compounds.
- Monitor 7-OH Levels: For those dealing with natural kratom, rigorous third-party testing is essential to ensure that 7-OH concentrations remain well below the proposed 0.050% threshold.
- Engage in Regulatory Feedback: Utilize the ongoing public comment period for 7-OH to advocate for clear definitions and to ensure that policy decisions are based on accurate, peer-reviewed data.
As the industry navigates these turbulent regulatory waters, one thing is certain: the DEA is committed to curbing the rise of synthetic opioids in the marketplace. The coming months will likely see further enforcement actions as the agency seeks to reconcile the popularity of kratom-derived products with the absolute necessity of protecting public health from highly potent, addictive substances.
This analysis was prepared by industry experts focused on regulatory affairs within the botanical and pharmaceutical sectors. Stakeholders are encouraged to consult with legal counsel to ensure full compliance with the evolving requirements of the Controlled Substances Act.
About the Author
